Stromedix secures broad patent coverage for lead program
MORE (PDF) >
Stromedix receives orphan drug designation for STX-100 in chronic allograft nephropathy
MORE (PDF) >
Stromedix raises $25 million in a Series B financing round
MORE (PDF) >
Bio-IT World
GO >
Mass High Tech
GO >
Xconomy.com
GO >
In Vivo Blog
GO >
BioCentury
GO >
 Company Fact Sheet
Download our Company Fact Sheet for information on who we are and what we do.
DOWNLOAD (PDF) >
Follow Stromedix on Twitter
GO >
|
|
 
STX-100 is Stromedix’s first clinical candidate and is being developed for the treatment of interstitial fibrosis and tubular atrophy in kidney transplant recipients and for idiopathic pulmonary fibrosis.
 |
Humanized monoclonal antibody to integrin αvβ6 |
|
Completed phase 1 clinical testing |
|
Provides localized, injury-specific inhibition of TGF-β activation
|
|
Significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease |
|
Broad therapeutic utility in chronic organ failure, acute organ failure and cancer |
|
